Most of the job cuts will be in Cambridge, Mass., the hub of Amgen’s neuroscience research, but some research and development positions in Thousand Oaks, Calif., and South San Francisco also will be affected.
Amgen’s exit from neuroscience research follows such other industry leaders as GlaxoSmithKline, Pfizer and AstraZeneca, which recently ended their work on neurological diseases.
More articles on pharmacy:
Novant Health leaders talk Walgreens partnership goals for 2020
Sanofi recalls heartburn drug over cancer risks
Centura Health opens retail pharmacy
